Pyxis Oncology, Inc.
corporate_fare Company Profile
Pyxis Oncology, Inc. (NASDAQ:PYXS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for PYXS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for PYXS spans 8-K, 10-Q, DEF 14A, PRE 14A.
Recent high-impact activity:
- Pyxis MICVO Data Mature: 39% cORR, 9.2-Month mDOR, 81% 12-Month OS in 2L+ HNSCC
- MICVO Response Rate Rises to 39% as Pyxis Plots Mid-2027 Phase 3
- Pyxis Doubles Authorized Shares to 380M After Stockholder Vote
- Pyxis Q3 Loss Narrows to $20.0M; Going Concern Warning Lifted, Runway to 1H 2028
- Pyxis Q3 Loss Narrows to $20.0M; Cash Runway Extended Into 1H 2028
Financial Snapshot
Short Interest & Short Volume
5.82 days to coverFINRA reported short interest of 4,525,205 shares in PYXS as of the October 30, 2026 settlement, a 4.1% increase from the prior period — about 5.8 days to cover at its recent average daily volume. On November 20, 2026, 40.8% of PYXS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for PYXS, detected from its recent SEC filings · based on capital-structure filings through 2026-11-13.
Authorized Shares Doubled to 380M · Large Potential Dilution Headroom
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →